115
Participants
Start Date
October 25, 2017
Primary Completion Date
December 20, 2019
Study Completion Date
January 6, 2020
TTP399
Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
TTP399
Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
Placebo Oral Tablet
Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Wake Forest, Winston-Salem
UNC Diabetes Care Center, Chapel Hill
Duke University Diabetes Research Clinic, Durham
PMG Research of Wilmington, Wilmington
Diabetes & Endocrinology Consultants, Morehead City
Mountain Diabetes and Endocrine Center, Asheville
Atlanta Diabetes Associate, Atlanta
Iowa Diabetes Research, West Des Moines
Intend Research, Norman
Dallas Diabetes Research Center, Dallas
University of Colorado Barbara Davis Center, Aurora
Rocky Mountain Diabetes Center, Idaho Falls
USC Westside Center for Diabetes, Beverly Hills
AMCR Institute, Escondido
University of Washington Medicine Diabetes Institute, Seattle
Lead Sponsor
Collaborators (1)
Juvenile Diabetes Research Foundation
OTHER
vTv Therapeutics
INDUSTRY